Rheumatoid ArthritisPhase 2LaunchPAD-RANCT07276581

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

A Phase 2 study testing AZD1163 in people with Rheumatoid Arthritis, run by AstraZeneca at 147 sites in 17 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Trial summary

Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163. Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Rheumatoid Arthritis
What is being tested?: AZD1163
Type of treatment: Injection or infusion
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 320 participants
Where: 147 sitesin 17 countries
Study dates: 15 Dec 2025to 18 Aug 2028
Phase: Phase 2
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Diagnosed with adult-onset RA as defined by the 2010 ACR/EULAR classification criteria for at least 12 weeks prior to screening.
Moderately-to-severely active RA as defined by: a. >= 6 swollen joints on 66SJC and >= 6 tender joints on 68TJC; b. CRP > upper limit of normal.
Have a positive ACPA at screening.
A history of inadequate response, or loss of response, or intolerance to: a. at least one csDMARD treatment, AND/OR b. At least one and at most 2 TNFi.
A history of at least 12 weeks treatment and >= 4 weeks stable on a csDMARD and/or SC TNFi prior to the day of randomisation.

Who cannot join

History or evidence of an alternate autoimmune or other condition that could confound the diagnosis of RA. Participants with RA and secondary Sjogren's disease are eligible.
Have received or planning to receive any biologic DMARDs (except for TNFi) or targeted synthetic DMARDs.

Trial locations and contacts

147 sites in 17 countries. Contact the study team or a site near you to ask about taking part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

Country

City, postcode or hospital

Sites recruiting now only

147 sites in 17 countries

United States29 sites, 23 recruiting

Research Site
Aurora, Colorado, 80045
Recruiting
Research Site
Austin, Texas, 78745
Recruiting
Research Site
Baltimore, Maryland, 21224
Recruiting
Research Site
Baytown, Texas, 77521
Recruiting
Research Site
Boynton Beach, Florida, 33435
Withdrawn
Research Site
Glendale, Arizona, 85306
Recruiting
Research Site
Henderson, Nevada, 89052
Recruiting
Research Site
Houston, Texas, 77027
Recruiting
Research Site
Houston, Texas, 77089
Recruiting
Research Site
Jacksonville, Florida, 32216
Withdrawn
Research Site
Kansas City, Missouri, 64151
Recruiting
Research Site
La Jolla, California, 92037
Recruiting
Research Site
Lake Charles, Louisiana, 70605
Recruiting
Research Site
Marietta, Georgia, 30060
Recruiting
Research Site
Mesquite, Texas, 75150
Recruiting
Research Site
Myrtle Beach, South Carolina, 29572
Recruiting
Research Site
New Bedford, Massachusetts, 02740
Recruiting
Research Site
Prescott Valley, Arizona, 86314
Withdrawn
Research Site
Rockville, Maryland, 20850
Not yet recruiting
Research Site
San Dimas, California, 91773
Withdrawn
Research Site
San Leandro, California, 94578
Recruiting
Research Site
Skokie, Illinois, 60076
Recruiting
Research Site
South Miami, Florida, 33143
Suspended
Research Site
St Louis, Missouri, 63131
Recruiting
Research Site
Tampa, Florida, 33607
Withdrawn
Research Site
Tomball, Texas, 77375
Recruiting
Research Site
Tucson, Arizona, 85748
Recruiting
Research Site
Willowbrook, Illinois, 60527
Recruiting
Research Site
Winter Haven, Florida, 33880
Recruiting

Other trials in United States

Japan17 sites, 15 recruiting

Research Site
Aomori, 030-8553
Recruiting
Research Site
Bunkyō City, 113-8655
Recruiting
Research Site
Fukuoka, 815-8555
Recruiting
Research Site
Hamamatsu, 430-0906
Recruiting
Research Site
Hitachi-Naka, 312-0057
Recruiting
Research Site
Iizuka-shi, 820-8505
Recruiting
Research Site
Kawachinagano-shi, 586-8521
Recruiting
Research Site
Matsuyama, 790-8524
Recruiting
Research Site
Meguro-ku, 152-8902
Recruiting
Research Site
Miyazaki, 880-0834
Recruiting
Research Site
Nagoya, 457-8511
Recruiting
Research Site
Okayama, 700-8557
Withdrawn
Research Site
Sagamihara-shi, 252-0315
Recruiting
Research Site
Sapporo, 060-0001
Withdrawn
Research Site
Sasebo-shi, 857-1195
Recruiting
Research Site
Sayama-shi, 350-1305
Recruiting
Research Site
Yokohama, 236-0037
Recruiting

Other trials in Japan

China15 sites, 15 recruiting

Research Site
Beijing, 100144
Recruiting
Research Site
Beijing, 100730
Recruiting
Research Site
Changchun, 130021
Recruiting
Research Site
Changsha, 410008
Recruiting
Research Site
Guangzhou, 510515
Recruiting
Research Site
Jiujiang, 332000
Recruiting
Research Site
Kunming, 650032
Not yet recruiting
Research Site
Linyi, CN-276003
Recruiting
Research Site
Nanchong, 637000
Recruiting
Research Site
Panjin, 124000
Recruiting
Research Site
Pingxiang, 337055
Recruiting
Research Site
Shantou, 515041
Recruiting
Research Site
Xuzhou, 221009
Recruiting
Research Site
Yangzhou, 225001
Recruiting
Research Site
Zhengzhou, 450000
Recruiting

Other trials in China

Mexico11 sites, 10 recruiting

Research Site
Chihuahua City, 31000
Recruiting
Research Site
Estado de México, 50090
Not yet recruiting
Research Site
Guadalajara, 44160
Not yet recruiting
Research Site
Guadalajara, 44650
Not yet recruiting
Research Site
Guadalajara, 44690
Not yet recruiting
Research Site
Gustavo A. Madero, 07300
Not yet recruiting
Research Site
Mérida, 97070
Not yet recruiting
Research Site
Mexicali, 021100
Not yet recruiting
Research Site
Mexico City, 06700
Recruiting
Research Site
Monterrey, 64460
Not yet recruiting
Research Site
San Luis Potosí City, 78213
Withdrawn

Other trials in Mexico

Ukraine9 sites, 9 recruiting

Research Site
Ivano-Frankivsk, 76018
Recruiting
Research Site
Kyiv, 02002
Recruiting
Research Site
Kyiv, 03037
Recruiting
Research Site
Kyiv, 03049
Recruiting
Research Site
Kyiv, 04050
Recruiting
Research Site
Kyiv, 04210
Recruiting
Research Site
Uzhhorod, 88000
Recruiting
Research Site
Vinnytsia, 21018
Recruiting
Research Site
Vinnytsia, 21029
Recruiting

Other trials in Ukraine

Hungary8 sites, 8 recruiting

Research Site
Budapest, 1023
Recruiting
Research Site
Budapest, 1027
Recruiting
Research Site
Budapest, 1036
Not yet recruiting
Research Site
Debrecen, 4032
Recruiting
Research Site
Gyula, 5700
Recruiting
Research Site
Szeged, 6725
Recruiting
Research Site
Székesfehérvár, 8000
Recruiting
Research Site
Veszprém, 8200
Recruiting

Other trials in Hungary

Brazil7 sites, 6 recruiting

Research Site
Juiz de Fora, 36010 570
Not yet recruiting
Research Site
Pelotas, 96040-010
Recruiting
Research Site
Porto Alegre, 90035-903
Recruiting
Research Site
Porto Alegre, 9061-000
Recruiting
Research Site
Salvador, 41820-020
Recruiting
Research Site
São Paulo, 04266-010
Withdrawn
Research Site
São Paulo, 05403-000
Not yet recruiting

Other trials in Brazil

Chile7 sites, 6 recruiting

Research Site
Providencia, 7510186
Withdrawn
Research Site
Santiago, 7500571
Recruiting
Research Site
Santiago, 7500587
Recruiting
Research Site
Temuco, 4810345
Recruiting
Research Site
Valdivia, 5110683
Recruiting
Research Site
Victoria, 4720097
Recruiting
Research Site
Viña del Mar, 2531172
Recruiting

Other trials in Chile

South Africa7 sites, 6 recruiting

Research Site
Brackenfell, 7560
Withdrawn
Research Site
Cape Town, 7500
Recruiting
Research Site
Durban, 4319
Recruiting
Research Site
Pinelands, 7405
Recruiting
Research Site
Pretoria, 0002
Recruiting
Research Site
Pretoria, 0083
Not yet recruiting
Research Site
Somerset West, 7130
Recruiting

Other trials in South Africa

Spain7 sites, 7 recruiting

Research Site
Barcelona, 08003
Recruiting
Research Site
Barcelona, 08035
Recruiting
Research Site
Barcelona, 08041
Recruiting
Research Site
Málaga, 29009
Recruiting
Research Site
Sabadell, 08208
Recruiting
Research Site
Santiago de Compostela, 15706
Recruiting
Research Site
Valencia, 46026
Recruiting

Other trials in Spain

Argentina6 sites, 6 recruiting

Research Site
Caba, C1128AAF
Recruiting
Research Site
Ciudad de Buenos Aires, C1015ABO
Recruiting
Research Site
Ciudad de Buenos Aires, C1428DUQ
Recruiting
Research Site
Córdoba, X5000EDC
Recruiting
Research Site
San Isidro, 1643
Recruiting
Research Site
San Miguel de Tucumán, T4000AXL
Recruiting

Other trials in Argentina

Bulgaria6 sites, 6 recruiting

Research Site
Haskovo, 6304
Recruiting
Research Site
Pleven, 5800
Recruiting
Research Site
Sofia, 1113
Recruiting
Research Site
Sofia, 1336
Recruiting
Research Site
Sofia, 1606
Recruiting
Research Site
Sofia, 1612
Recruiting

Other trials in Bulgaria

Poland5 sites, 5 recruiting

Research Site
Krakow, 30-002
Recruiting
Research Site
Krakow, 30-727
Recruiting
Research Site
Torun, 87-100
Recruiting
Research Site
Warsaw, 00-874
Recruiting
Research Site
Wroclaw, 50-244
Recruiting

Other trials in Poland

Canada4 sites, 4 recruiting

Research Site
Niagara Falls, Ontario, L2E 6A6
Not yet recruiting
Research Site
Ottawa, Ontario, K1V 1C1
Not yet recruiting
Research Site
Trois-Rivières, Quebec, G9A 3Y2
Recruiting
Research Site
Windsor, Ontario, N8X 5A7
Recruiting

Other trials in Canada

Germany4 sites, 3 recruiting

Research Site
Bad Doberan, 18209
Withdrawn
Research Site
Berlin, 10777
Recruiting
Research Site
Hamburg, 20095
Recruiting
Research Site
Sendenhorst, 48324
Recruiting

Other trials in Germany

United Kingdom4 sites, 3 recruiting

Research Site
Glasgow, G31 2ER
Recruiting
Research Site
Leeds, LS7 4SA
Recruiting
Research Site
Luton, LU4 0DZ
Recruiting
Research Site
Staffordshire, WS11 5XY
Withdrawn

Other trials in United Kingdom

Puerto Rico1 site, 1 recruiting

Research Site
Caguas, 00725
Recruiting

Other trials in Puerto Rico

About this study

Official title: A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)

Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.

Read the detailed description

AZD1163 is a novel bispecific antibody that inhibits the activity of extracellular peptidyl arginine deiminase 2 (PAD2) and peptidyl arginine deiminase 4 (PAD4) enzymes, which are responsible for protein citrullination. In RA, citrullinated proteins lead to the production of pathogenic anti-citrullinated peptide antibodies (ACPA).

This is a Phase II, randomised, double-blind, multicentre, 4 arm placebo-controlled study designed to evaluate the efficacy and safety of AZD1163 in ACPA + adults with moderate-to-severely active RA on standard of care (SoC) (conventional synthetic disease-modifying antirheumatic drugs [csDMARDs] or tumour necrosis factor inhibitor [TNFi] +/- csDMARD).

The study will have a screening period followed by a randomisation period wherein approximately 320 participants will be randomised in a 1:1:1:1 ratio to receive study intervention.

Participants will receive subcutaneous (SC) injection of one of three different doses of AZD1163 or placebo, along with SoC until Week 24 followed by a safety follow-up (FU) period of 28 weeks.

Conditions: Rheumatoid Arthritis
Being tested: AZD1163, Placebo
Keywords: Rheumatoid arthritis, AZD1163, placebo-controlled, double-blind, csDMARDs, TNFi, PAD2/4 inhibitor
Medical subject headings: Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

AZD1163Drug
Participants will receive SC injection of one of three different doses of AZD1163 in combination with SoC (csDMARD or TNFi +/- csDMARDSoC) until Week 24.
PlaceboOther
Participants will receive SC injection of placebo matched to AZD1163 in combination with SoC (csDMARD or TNFi +/- csDMARDSoC) until Week 24.

Study groups in NCT07276581
Study group	Role	What they receive
AZD1163 Dose 1	Experimental	Participants will receive subcutaneous (SC) injection of AZD1163 Dose 1 in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24. Receives: Drug: AZD1163
AZD1163 Dose 2	Experimental	Participants will receive SC injection of AZD1163 Dose 2 in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24. Receives: Drug: AZD1163
AZD1163 Dose 3	Experimental	Participants will receive SC injection of AZD1163 Dose 3 in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24. Receives: Drug: AZD1163
Placebo	Placebo comparator	Participants will receive SC injection of placebo matched with AZD1163 dose in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24. Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

Change From Baseline in Disease Activity Score-C-Reactive Protein (DAS28-CRP) at Week 12
Change from baseline in DAS28-CRP at Week 12.
Measured: Week 12

Secondary outcomes (6)

Percentage of Participants Achieving American College of Rheumatology Response Criteria 20 (ACR20) at Week 12
Proportion of participants achieving a 20% improvement in ACR response criteria at Week 12.
Measured: Week 12
Percentage of Participants Achieving ACR50 at Week 12
Proportion of participants achieving a 50% improvement in ACR response criteria at Week 12.
Measured: Week 12
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12
Change from baseline in CDAI at Week 12.
Measured: Week 12
Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12
Change from baseline in SDAI at Week 12.
Measured: Week 12
Summary statistics to evaluate the PK of AZD1163
AZD1163 concentrations in serum
Measured: Week 0 to Week 24 and Follow-Up
Summary statistics to evaluate the immunogenicity of AZD1163
ADA (incidence, prevalence, and titres)
Measured: Week 0 to Week 24 and Follow-Up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

15 Dec 202518 Aug 2028

First posted11 Dec 2025
Study start15 Dec 2025
Primary completion12 Nov 2027 (estimated)
Study completion18 Aug 2028 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Rheumatoid ArthritisStudies of the same condition, open and under way.
More trials run by AstraZenecaThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 320 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07276581
Sponsor's protocol ID: D9640C00003
Other IDs: 2025-522076-85, 167070, 2025
Acronym: LaunchPAD-RA
Status last verified: Oct 2026
First submitted: 1 Dec 2025
Last updated: 9 Oct 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Interested in taking part?

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

RecruitingPhase 2
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

All Rheumatoid Arthritis trials

Study at a glance

From the registry record, last updated by the sponsor on 9 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)
ClinicalTrials.gov ID: NCT07276581
Acronym / sponsor ID: LaunchPAD-RA / D9640C00003
Conditions: Rheumatoid Arthritis
Keywords: Rheumatoid arthritis, AZD1163, placebo-controlled, double-blind, csDMARDs, TNFi, PAD2/4 inhibitor
Phase: Phase 2
Study type: Interventional
Recruitment status: Recruiting
Enrolment: 320 participants (estimated)
Lead sponsor: AstraZenecaIndustry (pharma, biotech, devices)
Study start: 15 Dec 2025 (actual)
Primary completion: 12 Nov 2027 (estimated)
Study completion: 18 Aug 2028 (estimated)
First posted: 11 Dec 2025 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Phase II study in participants with moderately-to-severely active rheumatoid Arthritis (RA) to evaluate efficacy and safety of AZD1163.

Detailed description

The study will have a screening period followed by a randomisation period wherein approximately 320 participants will be randomised in a 1:1:1:1 ratio to receive study intervention.

Participants will receive subcutaneous (SC) injection of one of three different doses of AZD1163 or placebo, along with SoC until Week 24 followed by a safety follow-up (FU) period of 28 weeks.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind (participant, care provider, investigator, outcomes assessor)
Number of arms: 4

Arm	Type	Receives
AZD1163 Dose 1	Experimental	Drug: AZD1163Participants will receive subcutaneous (SC) injection of AZD1163 Dose 1 in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24.
AZD1163 Dose 2	Experimental	Drug: AZD1163Participants will receive SC injection of AZD1163 Dose 2 in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24.
AZD1163 Dose 3	Experimental	Drug: AZD1163Participants will receive SC injection of AZD1163 Dose 3 in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24.
Placebo	Placebo comparator	Other: PlaceboParticipants will receive SC injection of placebo matched with AZD1163 dose in combination with SoC (csDMARDs or TNFi +/- csDMARD) until Week 24.

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (5 listed)

Key exclusion criteria (2 listed)

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
AZD1163Participants will receive SC injection of one of three different doses of AZD1163 in combination with SoC (csDMARD or TNFi +/- csDMARDSoC) until Week 24.	Drug	AZD1163 Dose 1, AZD1163 Dose 2, AZD1163 Dose 3
PlaceboParticipants will receive SC injection of placebo matched to AZD1163 in combination with SoC (csDMARD or TNFi +/- csDMARDSoC) until Week 24.	Other	Placebo

Primary outcome

Change From Baseline in Disease Activity Score-C-Reactive Protein (DAS28-CRP) at Week 12
Time frame: Week 12
Change from baseline in DAS28-CRP at Week 12.

6 secondary outcomes

Percentage of Participants Achieving American College of Rheumatology Response Criteria 20 (ACR20) at Week 12
Time frame: Week 12
Percentage of Participants Achieving ACR50 at Week 12
Time frame: Week 12
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12
Time frame: Week 12
Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12
Time frame: Week 12
Summary statistics to evaluate the PK of AZD1163
Time frame: Week 0 to Week 24 and Follow-Up
Summary statistics to evaluate the immunogenicity of AZD1163
Time frame: Week 0 to Week 24 and Follow-Up

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2026.
Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Related trials for Rheumatoid Arthritis

RecruitingPhase 2
Study of PTC844 in Participants With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Not yet recruitingPhase 1
An Ascending Dose Study of DKB903 in Participants With Rheumatoid Arthritis (RA) and Participants With Systemic Lupus Erythematosus (SLE)
Rheumatoid Arthritis and Systemic Lupus Erythematosus
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

AstraZeneca Clinical Study Information Center contact

1-877-240-9479

information.center@astrazeneca.com

147 sites in 17 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing AZD1163 in people with Rheumatoid Arthritis, run by AstraZeneca at 147 sites in 17 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 9 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 147 sites in United States, Japan, China, Mexico, Ukraine and 12 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Disease Activity Score-C-Reactive Protein (DAS28-CRP) at Week 12 (time frame: Week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07276581.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2026.